An oral pill that tells your body to release more growth hormone and IGF-1 (a key growth signal). It's well-known for improving deep sleep, increasing appetite, and gradually building muscle while burning fat over time.
What to Expect
Week 1–2
Significant appetite increase within days. Improved sleep quality (deeper, more vivid dreams). Mild water retention and bloating. Lethargy possible.
Week 3–6
Enhanced recovery from training. Fat loss may begin despite appetite increase. Skin and hair improvements. Increased muscle fullness. Elevated IGF-1 on labs.
Week 8+
Substantial body recomposition. Bone density improvements. Sustained sleep quality. Hair growth. Some users note joint pain relief from increased GH.
Common Side Effects
Scientific Overview
Ibutamoren (MK-677) is an orally active, non-peptide growth hormone secretagogue mimicking ghrelin's action at the GHSR-1a receptor. It produces sustained 24-hour GH elevation and increases IGF-1 levels by 40–60% over baseline. Clinical trials in elderly subjects demonstrated improved lean body mass, bone mineral density, and sleep architecture (increased REM and Stage IV duration). Unlike exogenous GH, MK-677 preserves normal pulsatile GH secretion patterns. Notable side effects include appetite stimulation via hypothalamic ghrelin pathways and transient insulin resistance.
Dosing
10-25 mg by mouth daily, ideally before bed. Can be used long-term, but keep an eye on bloodwork.
Practical Guide
Storage
Store capsules/liquid at room temperature away from moisture and light. No reconstitution needed — oral compound.
Timing
Take before bed to align with natural GH pulse and sleep through appetite increase. Some take in the morning if appetite stimulation is desired.
Food
Can be taken with or without food. Taking with food may reduce nausea. Some users prefer empty stomach for maximum GH pulse.
Benefit Profile
Medical Considerations
Contraindications
- ✕Diabetes or pre-diabetes (raises fasting glucose)
- ✕Active cancer
- ✕Pituitary tumors
- ✕Pregnancy/nursing
- ✕Congestive heart failure (water retention)
Drug Interactions
Recommended Monitoring
- →Fasting glucose and HbA1c every 3 months
- →IGF-1 levels every 3 months
- →Monitor for edema
- →Fasting insulin levels
This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol.
Published Research
Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study.
MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.
The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms.
Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677.
Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a).
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.